In our cohort of patients, the main indications for switching to hormone replacement therapy were: inadequate control of albumin-adjusted total serum calcium level despite conventional treatment, kidney stones, and/or gastrointestinal intolerance to supplementation calcium/malabsorption [3, 4, 18]. The gene discussed is ALB; the disease is nephrolithiasis.